Evenamide

Evenamide

Clinical data
Other names	NW-3509; NW-3509A
ATC code	None
Identifiers
IUPAC name 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
CAS Number	1092977-61-1 Y
PubChem CID	25105689
ChemSpider	44208827
UNII	ON5S6N53JS
Chemical and physical data
Formula	C16H26N2O2
Molar mass	278.396 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCOc1cccc(CCNCC(=O)N(C)C)c1
InChI InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3 Key:GRHBODILPPXVKN-UHFFFAOYSA-N

Evenamide (INN) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Na_v1.3, Na_v1.7, and Na_v1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia. The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression. It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.

See also

• List of investigational antipsychotics

External links

• NW-3509 - Newron Pharmaceuticals
• NW-3509 - AdisInsight